1	The Simple One-step stool processing method for detection of Pulmonary
2	tuberculosis: a study protocol to assess the robustness, stool storage conditions
3	and sampling strategy for global implementation and scale-up
4	
5	Authors:
6	Petra de Haas ¹ , Bazezew Yenew ² , Getu Diriba ² , Misikir Amare ² , Andrii Slyzkyi ¹ , Yohannes
7	Demissie ³ , Bihil Sherefdin ³ , Ahmed Bedru ³ , Endale Mengesha ³ , Zewdu Gashu Dememew ³ ,
8	Abebaw Kebede ^{2,4,5} , Muluwork Getahun ² , Edine Tiemersma ¹ , Degu Jerene ¹
9	
10	¹ KNCV Tuberculosis Foundation, The Hague, The Netherlands; ² Ethiopian Public Health
11	Institute, Addis Ababa, Ethiopia; ³ KNCV Tuberculosis Foundation Ethiopia office, Addis
12	Ababa, Ethiopia; ⁴ Department of Microbial, Cellular and Molecular Biology, College of
13	Natural and Computational Sciences, Addis Ababa University, Addis Ababa, Ethiopia;
14	⁵ Africa CDC, Addis Ababa, Ethiopia.
15	
16	
17	
18	

19 Abstract

20 Background

Xpert MTB/RIF Ultra (Xpert-Ultra) provides timely results with good sensitivity and acceptable specificity with stool samples in children for bacteriological confirmation of tuberculosis (TB). This study aims to optimize the Simple One-Step (SOS) stool processing method for testing stool samples using the Xpert-Ultra in children and adults in selected health facilities in Addis Ababa, Ethiopia. The study is designed to assess the robustness of the SOS stool method, to help finetune the practical aspects of performing the test and to provide insights in stool storage conditions and sampling strategies before the method can be implemented and scaled in routine

28 settings in Ethiopia as well as globally.

29 Methods and design

30 The project "painless optimized diagnosis of TB in Ethiopian children" (PODTEC) will be a

31 cross sectional study where three key experiments will be carried out focusing on 1) sampling

32 strategy to investigate if the Xpert-Ultra *M.tuberculosis* (MTB) -positivity rate depends on stool

33 consistency, and if sensitivity can be increased by taking more than one stool sample from the

34 same participant, or doing multiple tests from the same stool sample, 2) storage conditions to

determine how long and at what temperature stool can be stored without losing sensitivity, and 3)

36 optimization of sensitivity and robustness of the SOS stool processing method by varying sample

37 processing steps, stool volume, and sampling from the stool-sample reagent mixture.

38 Stool samples will be collected from participants (children and adults) who are either sputum or

naso-gastric aspiration (NGA) and/or stool Xpert-Ultra MTB positive depending on the

40 experiment. Stool samples from these participants, recruited from 22 sites for an ongoing related

study, will be utilized for the PODTEC experiments. The sample size is estimated will be 50

42 participants.

43 We will use EpiData for data entry and Stata for data analysis purposes. The main analyses will

44 include computing the loss or gain in the Xpert-Ultra MTB positivity rate, and rates of

45 unsuccessful test results. The differences in the positivity rate regarding testing more than one

sample per child, different storage, and processing conditions, will be compared to the baseline

47 (on-site) Xpert-Ultra result.

48

49 Ethics and dissemination

- 50 The protocol was reviewed and approved by the Ethical Review Board of the Ethiopian Public
- 51 Health Institute (EPHI-IRB) (Protocol no EPHI-IRB-234-2020). The study results will be shared
- 52 with the national TB program and stakeholders to the benefit of further roll out of the test in a
- 53 routine Ethiopian setting. The results will also be disseminated in peer-reviewed scientific

54 journals.

55

56

57 Introduction

Approximately 1.09 million children globally fall ill with tuberculosis (TB) each year,, of whom only 399.000 are notified (1). Every day, nearly 700 children die from TB, 80% of them before reaching their fifth birthday. Treatment exists that could prevent nearly all these deaths, but less than 5% of children get treatment as childhood TB is difficult to diagnose (2).

62 The recent WHO guidelines recommend stool as non-invasive primary diagnostic samples for

testing with Xpert and Xpert Ultra for a diagnosis of TB among children (3, 4)based on evidence

64 from multiple studies summarized in three systematic literature reviews ((5), (6), (7). These

reviews showed the pooled sensitivities and specificities of stool Xpert against a microbiological

66 (sputum-based) reference standard of between 50 and 67% and 98-99%, respectively. The

67 reviews also showed that there was high heterogeneity in sensitivity which might be partly due to

using varying protocols for stool processing, with differences in reagents and methods of

69 homogenization and filtering (5). Moreover, most of the stool processing methods for Xpert

testing were rather quite complex and cannot be performed at the lower levels of the healthcare

system. This shows that there is a lack of standardized stool preparation and testing protocols and

72 warrants the optimization and standardization of the stool processing methods that can be used at

73 the decentralized level. The KNCV Tuberculosis Foundation (KNCV) and Ethiopian Public

Health Institute (EPHI) developed the Simple One-Step (SOS) stool processing method, which

can be applied in any GeneXpert laboratory (8).

76 This SOS stool processing method uses similar steps as sputum Xpert testing and does not

require additional materials or equipment other than an applicator to pick the correct stool

amount for testing. Since the method is as simple as sputum Xpert processing, it can be

79 performed at all sites where a GeneXpert instrument is functional after providing minimal

80 training to the staff involved in Xpert testing(8).

The SOS method has shown to be successful, with a low rate of unsuccessful results reported, in a demonstration study conducted in Ethiopia, in which multiple laboratories were involved (8). Furthermore, a head-to-head comparison study, in which the SOS method is compared to other stool processing methods showed similar sensitivity and specificity. The SOS stool method was most suitable for low-resource settings, because of its low error rate, processing time, and minimal requirements regarding biosafety precautions and laboratory equipment (9)

To gain more knowledge and in-depth experience on how the SOS stool processing method with

88 Xpert-Ultra would behave if included in the routine diagnostic pathway for (childhood) TB and

rolled out under the national TB program, we aim to further test and optimize the SOS

90 processing method for the detection of TB in stool by Xpert-Ultra and its ability to tolerate

91 perturbations (robustness). The study will also help to fine-tune standard operating procedures

92 (SOPs) for the SOS method.

93

94 Materials and Methods

95

96 Design plan

97 Study setup and period

This will be a cross-sectional study that will consist of a series of experiments on consecutive 98 99 stool samples collected from children and adults that are either sputum/NGA and/or stool Xpert-Ultra MTB positive. The study will be conducted in multiple health care facilities (>20) in Addis 100 101 Ababa, Ethiopia. The facilities have a relatively high number of TB patients and have experience 102 with participation in research. Children are being recruited for another related study, that 103 assesses the diagnostic accuracy of Xpert stool testing using the SOS stool processing method, called Alternatives to Sputum Testing for Tuberculosis in Indonesia and Ethiopia (ASTTIE), see 104 "S1 Figure". Therefore, MTB positive children who will be identified in the ASTTIE study will 105 106 also be used in the current study (PODTEC study). We will also recruit adults with MTB 107 detected in sputum from the same facilities. The study was originally planned to be carried out 108 till the end of 2020. However, due to the COVID-19 pandemic, the study period has been 109 extended.

110

111 Study population

Children aged ≤10 years from the ASTTIE study who are sputum/NGA and/or stool Xpert-Ultra MTB positive, and consecutive sputum Xpert MTB-positive adults presenting in the selected health facilities will constitute the study population. Eligible persons, or their caregivers will be requested to sign (parental) consent or assent, depending on the age of the participant. The exclusion criteria include being critically sick i.e., those who are in coma, terminally ill due to chronic debilitating co-morbidities, or other conditions determined to be "critical" by the treating

physician, being on TB treatment for longer than 5 days at the time of recruitment, and refusal to sign the informed consent.

120

121 Participant enrolment and stool collection

For children, the facility coordinator from the ASTTIE project will daily retrieve stool Xpert-Ultra results from the study sites and checks for eligibility. Parents of eligible children and eligible adults will be asked for informed consent for participation in this study, see "S1 appendix". For children, this is an additional consent to the consent already provided for the ASTTIE study. After enrolment in the study, for children, the remainder of the initial stool

127 sample (stool 1) will be collected and transported to EPHI. Participants will be provided with

128 two (children) or three (adults) large stool containers to allow collection of at least 30 grams of

- 129 stool. They will be instructed on how to collect and store the samples till delivery at the site.
- 130 Three appointments will be made to submit the additional stool samples. When the samples are

131 submitted, information will be collected on the stool submission form "S2 appendix" about the

- 132 date and time of collection at the household, storage conditions at the household and during
- transport and date and time of arrival at the site. To maximize the likelihood of finding MTB in
- the stool, the additional stool samples should be collected within 5 days after the participant's TB
- 135 treatment starts. Participants will be reimbursed for travel costs.

136 The stool samples will be kept in a cold chain at the site until they are transported to EPHI on the

137 same day. The site will inform the study coordinator which will assign a dedicated transporter for

- 138 this research purpose. The time between contacting the study coordinator and the pick-up of the
- 139 samples is expected to be within 2 hours after delivery on-site, which means that the samples

140 should arrive on the same day of collection at EPHI. After arrival at EPHI, the dedicated

- 141 laboratory technician will be ready to receive and register the samples and start the cascade of
- 142 experiments as shown in the sample flow diagram "S1 Figure 1".
- 143
- 144 Design of the experiments

145 In total three experiments are designed and the lay out is depicted in "S2 Figure" and "S3

146 Figure".

147 Experiment 1: Stool sample strategy

148 This experiment will investigate if, and by how much, the positivity rate of Xpert-Ultra on stool

149 increases when more than one sample from the same participant is tested. It also indicates how 150 homogeneous the Mycobacteria are distributed within the stool samples and across different 151 stools. Furthermore, it will provide insight in repeat testing if required due to unsuccessful test result, whether to advise to perform the repeat test from the same stool or from a fresh stool 152 153 sample. This will be done by testing three stools from the same participant collected during consecutive days (Experiment 1a) as well as three aliquots (North, South and East/West) from 154 155 the same stool sample (Experiment 1b). For children, two aliquots will be collected from the first 156 stool sample "S1 Figure 1". Aliquots will be tested using Xpert-Ultra, totaling a maximum of nine Xpert-Ultra tests per participant. 157

158

159 Experiment 2: Stool sample storage conditions

This experiment will investigate how long and under which conditions stool can be kept without 160 161 losing sensitivity to detect TB on Xpert-Ultra or increasing rates of unsuccessful tests. This is done by testing multiple aliquots taken from a known Xpert-Ultra MTB-positive stool sample 162 163 after storing aliquots from that Xpert-Ultra MTB-positive stool at three temperatures; a) 164 refrigerator 2-8°C, b) room temperature 20-22°C, and c) incubator 37°C and at four time periods; 2, 165 3, 5 and 10 days. These experiments will be done using aliquots remaining from the second and 166 third stool samples collected for Experiment 1. These stool samples are expected to have more 167 stools collected and probably the shortest storage time between collection at the site and 168 preparation at EPHI.

169

170 Experiment 3: Optimization and evaluating robustness of the SOS stool processing method

171 This experiment consists of a series of sub-experiments that will investigate if the SOS stool 172 processing method can be further optimized to increase its recovery rate to detect TB. Although 173 the SOS stool processing method is simple and contains minimal processing steps, certain steps might still be adapted to see if this influences the test's sensitivity. This is done by testing 174 175 multiple aliquots taken from a known Xpert-Ultra MTB-positive stool sample processed using 176 slightly different approaches. The first sub-experiment (3a) varies the incubation time and 177 shaking method during the processing of stool. The second sub-experiment (3b) assesses the optimum and maximum time and temperature for keeping the processed stool-sample reagent 178 179 mixture before Xpert testing is conducted on the different incubation steps. The third sub-

- 180 experiment (3c) assesses the optimum and maximum stool volume.
- 181 Stool consistency and bacterial load are two important factors that might influence the outcome
- 182 of the experiments. Therefore, samples with different consistency and bacterial load will be
- 183 included in all experiments.
- 184 If the Xpert-Ultra result is unsuccessful (i.e., the result is "invalid" or "error"), the test will NOT
- 185 be repeated as this is part of the study outcome.
- 186 The SOS stool method's comprehensive instructions can be found on KNCV website (10). In "S3
- 187 appendix" a schematic overview of the SOS stool method is provided. Depending on the stool
- 188 consistency the protocol for solid stool or liquid stool is followed.
- 189

190 Sampling plan

191 Variables and outcome measures

- 192 The primary outcome measure will be the Xpert-Ultra MTB quantitative result and positivity rate
- 193 of stool specimens processed using the SOS stool processing method under the different
- 194 experimental conditions will be compared to the baseline (on-site) Xpert-Ultra MTB positive test
- result of stool processed using the SOS stool processing method.
- 196 The secondary outcome measure will be the rate of Xpert-Ultra unsuccessful test results.
- 197

198 Sample size199

- 200 At the selected health facilities, a maximum of 750 children with presumptive TB will be
- 201 enrolled in ASTTIE during the recruitment period of this study. With Xpert-Ultra MTB-
- 202 positivity rate of 5%, up to 32 children will be available for the optimization exercises. We aim
- to supplement this with up to 50 participants by also recruiting adults from the health facilities
- 204 participating in ASTTIE, as described above. Thus, for the experiments, we will have stool
- samples for around 50 individuals available, totaling a maximum of 150 stool samples.
- 206 "S4 Figure" indicates the minimum rates of conversion (Xpert MTB- to Xpert MTB+),
- 207 respectively reversion (Xpert MTB+ to Xpert MTB-), that can be picked up with statistical
- 208 significance with this sample size.
- 209

210 Analysis plan and data collection

211

- 212 Data will be collected on age and sex of the participant, TB suggestive symptoms and TB contact
- 213 history, Xpert-Ultra result for the initial stool (children only) and sputum/NGA sample, date, and
- 214 place (participant's home or health facility) of stool of collection, date of stool receipt at the
- 215 NTRL, stool storage and transport temperature until receipt at the NTRL, and stool consistency.
- 216 Detailed information on the experiments' conditions will also be collected as well as the cycle
- 217 threshold (Ct) values for all probes and error codes in case of errors.
- 218

219 Data entry, storage, and management

- Each stool sample will be submitted to EPHI together with a stool submission form "S2
- appendix". Details when conducting the experiment are collected on the experiment form "S4
- appendix". The forms are stored at EPHI. All data will be entered into pre-structured EpiData
- files (EpiData version 3.1; www.epidata.dk). A random 10% of the data will be re-entered in a
- separate file to check the quality of data entry. If more than 3% of errors are found in key
- variables (experiment conditions and Xpert result), full double data entry will be conducted.
- 226

227 Data interpretation

- 228 The main study outcome is the semi-quantitative Xpert Ultra result as provided by the
- 229 GeneXpert instrument (trace, very low, low, medium, high, error, invalid or no result),
- 230 interpreted as per the manufacturer's instructions. The individual probes' Ct values are the main
- 231 quantitative study outcomes. We consider higher Ct values to represent lower bacillary loads, as
- these indicate that more PCR cycles are needed to reach the threshold of MTB detected. Error
- codes will be interpreted following the manufacturer's guidance to understand the likely cause ofthe error.
- 235

236 Statistical analysis

Statistical analysis will be performed by the STATA/SE (version 15; StataCorp) statistical
software package. The Xpert-Ultra stool result from each aliquot will be compared with the
baseline Xpert-Ultra. Trends in the proportion of samples being MTB-positive and the
proportion of samples with unsuccessful results over e.g., increasing storage time or temperature,
or increasing amounts of stool added, will be analyzed using Wilcoxon-like test for trend of

across ordered groups using nptrend (11). Logistic regression will be applied to assess factors

associated with stool MTB positivity and unsuccessful test outcomes. We will assess if there is

indication that stool samples are nested into individual participants, just as aliquots of one stool

sample may be nested into individual stool samples, by comparing the outcomes of simple

246 (multivariate) logistic regression to the outcomes of multilevel mixed-effects logistic regression

247 using the likelihood-ratio test to determine the best model fit.

248

249 Ethical considerations

250 The study obtained ethical clearance from the Review Boards of the Ethiopian Public Health

251 Institute (EPHI-IRB) (Protocol no EPHI-IRB-234-2020). The project will follow the routine

252 procedure of patients' recruitment into studies, follow-up, and analysis as well as drawing of

conclusions. Informed parental consent will be obtained from the children's legal guardians.

254 Participants' information will be kept confidential, and the digital files used for analysis will

255 only have the PODTEC laboratory code and ASTTIE unique person identification code (UPIC)

and will not contain any names or other personal identifying information of the participant.

257 Participants' information will be kept confidential, and the digital files used for analysis will

only have the PODTEC laboratory code and the ASTTIE UPIC and will not contain any names

259 or other personal identifying information of the participant.

260

261 Discussion

This is the first study protocol in which the sampling strategy and robustness of a stool 262 processing method will be investigated. Based on the experiment's findings, certain steps in the 263 264 current SOP of the SOS stool method might be adjusted. The experiments will be performed 265 using samples from presumptive TB cases, so for the patients for whom the test will be used in practice in a country with a relatively high TB burden. Uniquely, stool samples will not be 266 267 spiked with mycobacteria as in other studies (9), (12). We expect that the MTB distribution is 268 different in the stool samples from TB patients than in the spiked stools. Moreover, we will 269 include children who have mostly have paucibacillary TB and who will benefit most from stool 270 Xpert testing, as they cannot easily provide sputum. The study population will be drawn from 271 locations where the test is expected to be conducted in the future, providing more realistic 272 insights in the possibility of implementing the method in routine and collection of multiple

samples.

274 The experiments are based on the controlled simulation of plausible scenarios, i.e. situations that

275 can occur in practice, such as long transit times at high temperatures, long contact time of stool

with the sample reagent before Xpert testing, variation in the stool portion size picked for

277 processing, and variation in sample processing. The outcome will provide insights of the

278 robustness of the method and will show how far certain steps can be stretched. It will provide

279 practical outcomes that will enable the laboratory personnel and healthcare professionals

involved in the stool testing to implement the most optimal protocol.

281 The main results will be presented both at local and international scientific meetings. The results

will also be disseminated in the form of peer reviewed publications and as policy briefs. Key

audiences for the dissemination will include global scientific advisory group members, local

technical advisory committee (TAC) members and NTP. Study host communities will also be

informed about the key results of the study through appropriate popular media.

286

287 Acknowledgements

We would like to acknowledge the Ethiopian Public Health Institute and KNCV Tuberculosis Foundation. We would also like to thank all healthcare facilities that will participate in the study by recruiting the study participants. We would further like to acknowledge Mamush Sahile from KNCV Ethiopia for his assistance in the study.

292

293 Author contribution

- 294 Conceptualization: PdH, BY, AS, EWT, DJ
- 295 Data curation: BY, GD, MA, BS
- 296 Formal analysis: EWT, BY, PdH
- 297 Funding acquisition: EWT, PdH, DJ, AB
- 298 Investigation: PdH, BY, GD, AS, BS, EM, EWT, DJ
- 299 Methodology: PdH, BY, GD, MA, AS, BS, EM, ZGD, AK, MG, EWT, DJ
- 300 Project administration: DJ, BY, YD, BS, EM, ZGD, AB

- 301 Resources: DJ
- 302 Software: EWT
- 303 Supervision: PdH, EWT, DJ, BY, GD, MA, AS, YD, BS, EM, ZGD, AK, MG, AB
- 304 Validation: EWT
- 305 Visualization: EWT, PdH
- 306 Writing- original draft: DJ, PdH, EWT, BY
- 307 Writing- review & editing: all authors
- 308 References
- 309
- 310 1. WHO. Global tuberculosis report 2021. World Health Organisation; 2021.
- 311 2. WHO. Roadmap towards ending TB in children and adolescents. 2018.
- 312 3. WHO. WHO operational handbook on tuberculosis. Module 3: Diagnosis. World Health
- 313 Organisation; 2021.
- WHO. Rapid communication on updated guidance on the management of tuberculosis in children
 and adolescents. World Health Organisation; 2021.
- MacLean E, Sulis G, Denkinger CM, Johnston JC, Pai M, Ahmad Khan F. Diagnostic Accuracy
 of Stool Xpert MTB/RIF for Detection of Pulmonary Tuberculosis in Children: a Systematic Review and
 Meta-analysis. J Clin Microbiol. 2019;57(6).
- Mesman AW, Rodriguez C, Ager E, Coit J, Trevisi L, Franke MF. Diagnostic accuracy of
 molecular detection of Mycobacterium tuberculosis in pediatric stool samples: A systematic review and
- 321 meta-analysis. Tuberculosis (Edinb). 2019;119:101878.
- 322 7. Gebre M, Cameron LH, Tadesse G, Woldeamanuel Y, Wassie L. Variable Diagnostic
- Performance of Stool Xpert in Pediatric Tuberculosis: A Systematic Review and Meta-analysis. Open
 Forum Infect Dis. 2021;8(8):ofaa627.
- de Haas P, Yenew B, Mengesha E, Slyzkyi A, Gashu Z, Lounnas M, et al. The Simple One-Step
 (SOS) Stool Processing Method for Use with the Xpert MTB/RIF Assay for a Child-Friendly Diagnosis
 of Tuberculosis Closer to the Point of Care. J Clin Microbiol. 2021;59(8):e0040621.
- Jasumback CL, Dlamini Q, Kahari J, Maphalala G, Dlamini MG, Dube GS, et al. Laboratory
- comparison of stool processing methods for Xpert(®) Ultra. Public Health Action. 2021;11(2):55-7.
- KNCV. SOS stoolbox, implementation package of the SOS stool methode 2021 [Available from:
 https://www.kncvtbc.org/en/sos-stoolbox/.
- 332 11. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4(1):87-90.
- 333 12. Lounnas M, Diack A, Nicol MP, Eyangoh S, Wobudeya E, Marcy O, et al. Laboratory
- development of a simple stool sample processing method diagnosis of pediatric tuberculosis using Xpert
- 335 Ultra. Tuberculosis (Edinb). 2020;125:102002.
- 336
- 337



* Site of action is depicted with blue background boxes; and stool samples are in yellow boxes. Abbreviations used: ASTTIE; Alternatives to Sputum Testing for Tuberculosis in Indonesia and Ethiopia, PODTEC: Painless Optimized Diagnosis of TB in Ethiopian Children, NTRL: National TB Reference Laboratory, NGA: Naso-Gastric Aspiration, MTB: *M.tuberculosis*, GX; GeneXpert, Exp.: Experiment

Figure 1: Study flow diagram representing steps from inclusion of adults and children to arrival of the stool samples at EPHI and their allocation to the different experiments.

Figure 1



* Repeat if ≥2 test results are unsuccessful

Abbreviations used: MTB, M. tuberculosis; N, North; S, South; E/W, East or West; Exp, experiment; RT, room temperature; H, hours; SR, sample reagent.

Figure 2. Overview of experiments. Arrows indicate what experiments are done with the different stool specimens. Note that for adult participants, in principle all experiments will be done on all three stool samples, provided that enough stool is collected per bowel movement.







Figure 3 Overview of assigning Stool to the Experiments outlined in figure 2. Note that for adults, in principle, all experiments will be conducted if there is enough stool available per sample.

Figure 3

	Shifting	Shifting	from - to +									
	from + to -	0%	1%	2%	3%	4%	5%	10%	15%	20%	25%	30%
	0%	infinite	883	441	293	219	175	87	57	42	33	27
	1%	883	infinite	2453	833	468	317	116	69	49	38	30
	2%	441	2453	infinite	4023	1225	642	158	85	57	42	34
	3%	293	833	4023	infinite	5592	1618	221	105	66	48	37
	4%	219	468	1225	5592	infinite	7162	320	130	78	54	41
	5%	175	317	642	1618	7162	infinite	489	165	92	62	46
	10%	87	116	158	221	320	489	infinite	803	244	127	82
	15%	57	69	85	105	130	165	803	infinite	1117	322	162
	20%	42	49	57	66	78	92	244	1117	infinite	1431	401
	25%	33	38	42	48	54	62	127	322	1431	infinite	1745
medRxiv prepr	int doi: https://doi.org/1	27 0.1101/2022.02 review) is the	.04.22270430; author/funder.	this version pos	sted February 5 1 medRxiv a lic	, 2022. The cop	yright holder fo	or this preprint	162	401	1745	infinite

It is made available under a CC-BY 4.0 International license .

: number can be reached if all 3 stool samples are used in the experiment

: number can be reached if 2 stool samples are used in the experiment



: number can be reached if 1 stool sample is used in the experiment

Colored cells show what minimum proportional changes can be picked up with 1-3 stools from 35 children (i.e.,

max. 35-105 samples). Note that this calculation does not consider correlation between stool samples from the same individual.

Figure 4: Sample size by minimum changes in positivity rate (from MTB-positive to -negative, and from MTB-negative to -positive Xpert-Ultra result), calculated using the Statulator; (11).

Figure 4